Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial
Nakachi K, Ikeda M, Konishi M, Nomura Skatayama H, Kataoka T, et al on behalf of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG).
Lancet 2023; 401: 195-203.
In this study that included 440 procedures, after a median of 45.4 months, adjuvant S-1 therapy given for four cycles improved overall survival from 67.6 to 77.1 per cent, P=0.008.
Comment: A benchmark study for this rare condition, that provides a real hope of improved survival.
6 March 2023
Read paperAcademy
Part of the charitable activity of the Society, BJS Academy is an online educational resource for current and future surgeons.
The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.
